Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (note: input metadata referenced "Scinai Immunotherapeutics Ltd." but the filing text identifies the registrant as BiondVax) covers the month of November 2016, with a report date of November 4, 2016. The company is a foreign private issuer based in Ness Ziona, Israel, focused on pharmaceutical development.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a material definitive agreement regarding capital raising.
- Capital Raise Capacity: Up to $150,000,000 via a shelf registration statement (Form F-3).
- Instrument: American Depositary Shares (ADSs), where each ADS represents 40 ordinary shares.
- Transaction Fees: 3.0% commission to FBR Capital Markets & Co. and up to 2.0% fee to Aegis Capital Corp. on gross sales.
Material Changes
The primary material change is the entry into an "At The Market" (ATM) Issuance Sales Agreement with FBR Capital Markets & Co. This agreement allows the company to sell ADSs through an "at the market offering" program, including sales on the Nasdaq Capital Market or through market makers. This follows the filing of a shelf registration statement to facilitate these sales.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, operational outlook, or management commentary regarding future earnings or clinical trial results. The primary contingency noted is the termination of the ATM Agreement, which will occur upon the earliest of: (1) the sale of all Placement Shares subject to the agreement, or (2) termination in accordance with the agreement's terms. The document includes standard legal disclaimers stating it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the exact number of ADSs sold and total proceeds generated under the ATM program since November 4, 2016.
- Confirm the current cash position and burn rate to assess the necessity of the full $150 million raise.
- Review the impact of the 5.0% total fee structure (3.0% to FBR + 2.0% to Aegis) on net capital raised.
- Check for any subsequent filings regarding the termination of the ATM agreement or the sale of all authorized shares.